ArticleIJID regions2026
Update and optimization of a multiplex RT-qPCR assay to overcome diagnostic failure in emerging influenza A(H3N2) subclades J.2 and K (Peru, 2024-2026).
Article in IJID regions, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Continuous genetic drift in the hemagglutinin gene of influenza A(H3N2) viruses compromises the reliability of standard molecular diagnostics, resulting in target dropouts and epidemiological surveillance gaps. This study evaluated the clinical performance of the World Health Organization (WHO)-recommended (2024) real-time reverse transcription-quantitative polymerase chain reaction (RT-qPCR) sets against emerging Peruvian A(H3N2) subclades J.2 and K, and developed an optimized dual-target multiplex assay to restore diagnostic sensitivity. Methods: Genomic sequencing was used to identify mutational profiles in circulating Peruvian A(H3N2) subclades J.2 and K. Standard WHO (2024) oligonucleotides were tested against 20 A(H3N2)-confirmed clinical samples. The dual-target multiplex RT-qPCR assay was then redesigned with targeted bioinformatic modifications and validated. Results: Genomic analysis identified critical oligonucleotide mismatches in both subclades. Consequently, the standard WHO assay failed to detect the virus in any tested isolate. The optimized multiplex assay successfully restored amplification in all 20 sequencing-confirmed A(H3N2) viruses. It demonstrated high analytical concordance (Pearson's r = 0.70, Conclusion: The optimized dual-target RT-qPCR assay successfully overcomes the diagnostic failure of standard probes, providing a reliable, fail-safe mechanism for detecting currently circulating H3N2 variants. These findings emphasize the necessity of routine genomic audits to maintain current molecular protocols designed for detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.